162 related articles for article (PubMed ID: 24566881)
21. Analysis of the CK2-dependent phosphorylation of serine 13 in Cdc37 using a phospho-specific antibody and phospho-affinity gel electrophoresis.
Miyata Y; Nishida E
FEBS J; 2007 Nov; 274(21):5690-703. PubMed ID: 17922836
[TBL] [Abstract][Full Text] [Related]
22. ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.
Pankow S; Bamberger C; Calzolari D; Martínez-Bartolomé S; Lavallée-Adam M; Balch WE; Yates JR
Nature; 2015 Dec; 528(7583):510-6. PubMed ID: 26618866
[TBL] [Abstract][Full Text] [Related]
23. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
Yeh JT; Yu YC; Hwang TC
J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
[TBL] [Abstract][Full Text] [Related]
24. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134
[TBL] [Abstract][Full Text] [Related]
25. Identification of protein kinase A phosphorylation sites on NBD1 and R domains of CFTR using electrospray mass spectrometry with selective phosphate ion monitoring.
Townsend RR; Lipniunas PH; Tulk BM; Verkman AS
Protein Sci; 1996 Sep; 5(9):1865-73. PubMed ID: 8880910
[TBL] [Abstract][Full Text] [Related]
26. Cystic fibrosis as a bowel cancer syndrome and the potential role of CK2.
Mehta A
Mol Cell Biochem; 2008 Sep; 316(1-2):169-75. PubMed ID: 18604476
[TBL] [Abstract][Full Text] [Related]
27. The PEST sequence does not contribute to the stability of the cystic fibrosis transmembrane conductance regulator.
Chen EY; Clarke DM
BMC Biochem; 2002 Oct; 3():29. PubMed ID: 12361483
[TBL] [Abstract][Full Text] [Related]
28. Differential function of the two nucleotide binding domains on cystic fibrosis transmembrane conductance regulator.
Nagel G
Biochim Biophys Acta; 1999 Dec; 1461(2):263-74. PubMed ID: 10581360
[TBL] [Abstract][Full Text] [Related]
29. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.
Vilk G; Weber JE; Turowec JP; Duncan JS; Wu C; Derksen DR; Zien P; Sarno S; Donella-Deana A; Lajoie G; Pinna LA; Li SS; Litchfield DW
Cell Signal; 2008 Nov; 20(11):1942-51. PubMed ID: 18662771
[TBL] [Abstract][Full Text] [Related]
30. A short segment of the R domain of cystic fibrosis transmembrane conductance regulator contains channel stimulatory and inhibitory activities that are separable by sequence modification.
Xie J; Adams LM; Zhao J; Gerken TA; Davis PB; Ma J
J Biol Chem; 2002 Jun; 277(25):23019-27. PubMed ID: 11950844
[TBL] [Abstract][Full Text] [Related]
31. Antagonistic regulation of cystic fibrosis transmembrane conductance regulator cell surface expression by protein kinases WNK4 and spleen tyrosine kinase.
Mendes AI; Matos P; Moniz S; Luz S; Amaral MD; Farinha CM; Jordan P
Mol Cell Biol; 2011 Oct; 31(19):4076-86. PubMed ID: 21807898
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508.
DeCarvalho AC; Gansheroff LJ; Teem JL
J Biol Chem; 2002 Sep; 277(39):35896-905. PubMed ID: 12110684
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase CK2 interacts with Chk2 and phosphorylates Mre11 on serine 649.
Kim ST
Biochem Biophys Res Commun; 2005 May; 331(1):247-52. PubMed ID: 15845385
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the localization of STE6/CFTR chimeras in a Saccharomyces cerevisiae model for the cystic fibrosis defect CFTR delta F508.
Paddon C; Loayza D; Vangelista L; Solari R; Michaelis S
Mol Microbiol; 1996 Mar; 19(5):1007-17. PubMed ID: 8830258
[TBL] [Abstract][Full Text] [Related]
35. The gating of the CFTR channel.
Moran O
Cell Mol Life Sci; 2017 Jan; 74(1):85-92. PubMed ID: 27696113
[TBL] [Abstract][Full Text] [Related]
36. A conserved region of the R domain of cystic fibrosis transmembrane conductance regulator is important in processing and function.
Pasyk EA; Morin XK; Zeman P; Garami E; Galley K; Huan LJ; Wang Y; Bear CE
J Biol Chem; 1998 Nov; 273(48):31759-64. PubMed ID: 9822639
[TBL] [Abstract][Full Text] [Related]
37. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator.
Younger JM; Chen L; Ren HY; Rosser MF; Turnbull EL; Fan CY; Patterson C; Cyr DM
Cell; 2006 Aug; 126(3):571-82. PubMed ID: 16901789
[TBL] [Abstract][Full Text] [Related]
38. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.
Lewis HA; Zhao X; Wang C; Sauder JM; Rooney I; Noland BW; Lorimer D; Kearins MC; Conners K; Condon B; Maloney PC; Guggino WB; Hunt JF; Emtage S
J Biol Chem; 2005 Jan; 280(2):1346-53. PubMed ID: 15528182
[TBL] [Abstract][Full Text] [Related]
39. Calnexin Delta 185-520 partially reverses the misprocessing of the Delta F508 cystic fibrosis transmembrane conductance regulator.
Okiyoneda T; Wada I; Jono H; Shuto T; Yoshitake K; Nakano N; Nagayama S; Harada K; Isohama Y; Miyata T; Kai H
FEBS Lett; 2002 Aug; 526(1-3):87-92. PubMed ID: 12208510
[TBL] [Abstract][Full Text] [Related]
40. Defects in processing and trafficking of cystic fibrosis transmembrane conductance regulator.
Kunzelmann K; Nitschke R
Exp Nephrol; 2000; 8(6):332-42. PubMed ID: 11014930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
